Although the clinical trial is closed to new participants, our clinic remains involved in the nationwide study called “The Safety and Efficacy of SYD-101 in Children with Myopia (STAAR – clinicaltrials.gov identifier: NCT03918915)”.
It is a four year, double-masked, randomized controlled study looking at the long term effects of low-dose atropine as well as any rebound effects in children ages 3-14. Because atropine is not currently labeled by the FDA for the treatment of Myopia, the company Sydnexis is seeking FDA approval for a new formulation of low concentration atropine with 0.01% and 0.03%.